This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
TEVA announced on July 27th its intention to withdraw its unsolicited expression of interest to acquire rival Mylan N.V., a leading global pharmaceutical company with a growing portfolio of around 1,400 generic pharmaceuticals and brand medications.
A CRA team provided economic support to Mylan in its antitrust defense in front of the European Commission against the attempted hostile take-over.
The high-profile acquisition of Activision by Microsoft, which CRA Competition’s teams advised on was named overall Matter of the Year, as well as Matter of...
CRA’s Dr. Benno Buehler and Kilian Mueller show that several concerns over the European Commission’s proposal for a regulation on standard essential patents...
CRA is a proud sponsor of the event. Sam Marden is a panelist during the session titled “Exploring the Application of Recent Merger Control Developments to...
Raphaël De Coninck is a speaker on the panel on tools and practices for effective and timely management of merger cases, acting as a Non-Governmental Advisor...
